AcLysValCit-PABC-DMAE-SW-163D is a drug-linker conjugates for ADC which consists of a natural bis-intercalator, SW-163D, conjugated via an AcLysValCitPABC-DMAE linker[1].

SW-163D is a cyclodepsipeptide antibiotic that is isolated from Streptomyces sp. SW-163D also exhibits antitumour activity. PF06888667 is a potent, stable, and efficacious ADC that consists of the bis-intercalator, SW-163D, conjugated via an N-acetyl-lysine-valine-citrulline-p-aminobenzyl alcohol-N,N-dimethylethylenediamine (AcLysValCitPABC-DMAE) linker to an engineered variant of the anti-Her2 mAb, trastuzumab, catalyzed by transglutaminase[1].

2411007-69-5

C85H113N19O22S2

1817.05

AcLysValCit-PABC-DMAE-SW-163D

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years